Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Operating Expenses (2019 - 2025)

Goldenwell Biotech's Operating Expenses history spans 7 years, with the latest figure at $30885.0 for Q3 2025.

  • For Q3 2025, Operating Expenses rose 47.32% year-over-year to $30885.0; the TTM value through Sep 2025 reached $127033.0, up 7.04%, while the annual FY2024 figure was $123162.0, 5.73% up from the prior year.
  • Operating Expenses reached $30885.0 in Q3 2025 per GWLL's latest filing, down from $40620.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $920332.0 in Q4 2022 to a low of -$150479.0 in Q4 2021.
  • Average Operating Expenses over 5 years is $60939.4, with a median of $28751.0 recorded in 2022.
  • The largest YoY upside for Operating Expenses was 10658.37% in 2021 against a maximum downside of 16632.19% in 2021.
  • A 5-year view of Operating Expenses shows it stood at -$150479.0 in 2021, then surged by 711.6% to $920332.0 in 2022, then crashed by 97.73% to $20872.0 in 2023, then grew by 11.4% to $23251.0 in 2024, then surged by 32.83% to $30885.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Operating Expenses are $30885.0 (Q3 2025), $40620.0 (Q2 2025), and $32277.0 (Q1 2025).